CONSOLIDATED STATEMENT OF EQUITY - USD ($) $ in Thousands	Total	Acquisitions And Asset Purchases	DeepHealth, Inc.	Radnet, Inc. Stockholders' Equity	Radnet, Inc. Stockholders' Equity Acquisitions And Asset Purchases	Radnet, Inc. Stockholders' Equity DeepHealth, Inc.	Common Stock	Common Stock Acquisitions And Asset Purchases	Common Stock DeepHealth, Inc.	Additional Paid-in Capital	Additional Paid-in Capital Acquisitions And Asset Purchases	Additional Paid-in Capital DeepHealth, Inc.	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2019							50,314,328
Beginning balance, value at Dec. 31, 2019	$ 233,139			$ 151,685			$ 5			$ 262,865			$ (8,026)	$ (103,159)	$ 81,454
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under the equity compensation plan (in shares)							491,674		10,920
Stock-based compensation expense	12,463			12,463						12,463
Issuance of common stock for sale of unregistered securities for the DeepHealth acquisition (in shares)							823,615
Issuance of common stock for acquisitions	33,011			33,011						33,011
Tax effect on gain on sale of noncontrolling interest	(551)			(551)						(551)
Distributions paid to noncontrolling interests	(1,985)														(1,985)
Change in cumulative foreign currency translation adjustment	(101)			(101)									(101)
Change in fair value cash flow hedge, net of taxes	(19,372)			(19,372)									(19,372)
Change in fair value of cash flow hedge from prior periods reclassified to earnings	3,448			3,448									3,448
Net income (loss)	(1,749)			(14,840)										(14,840)	13,091
Ending balance (in shares) at Dec. 31, 2020							51,640,537
Ending balance, value at Dec. 31, 2020	258,303			165,743			$ 5			307,788			(24,051)	(117,999)	92,560
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock upon exercise of options (in shares)							53,960
Issuance of stock upon exercise of options	488			488						488
Shares issued under the equity compensation plan (in shares)							1,212,758		471,162
Stock-based compensation expense	25,284			25,284						25,284
Distributions paid to noncontrolling interests	(2,426)														(2,426)
Change in cumulative foreign currency translation adjustment	(65)			(65)									(65)
Change in fair value cash flow hedge, net of taxes	0
Change in fair value of cash flow hedge from prior periods reclassified to earnings	3,695			3,695									3,695
Net income (loss)	44,319			24,727										24,727	19,592
Issuance of stock for acquisitions (in shares)								82,658	91,517
Issuance of stock for acquisitions		$ 2,498	$ 2,413		$ 2,498	$ 2,413					$ 2,498	$ 2,413
Forfeiture of restricted stock (in shares)							(4,365)
Forfeiture of restricted stock	(81)			(81)						(81)
Gain on contribution of assets to majority owned subsidiary	(4)			(4)						(4)
Contribution from noncontrolling partner	123														123
Sale to noncontrolling interests, net of taxes	$ 11,610			4,206						4,206					7,404
Ending balance (in shares) at Dec. 31, 2021	53,548,227						53,548,227
Ending balance, value at Dec. 31, 2021	$ 346,157			228,904			$ 5			342,592			(20,421)	(93,272)	117,253
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock upon exercise of options (in shares)	25,000		203,678				25,000
Issuance of stock upon exercise of options	$ 295			295			$ 1			294
Shares issued under the equity compensation plan (in shares)							725,577		204,160
Issuance of common stock to settle DeepHealth contingent consideration (in shares)									781,577
Stock-based compensation expense	23,543			23,543						23,543
Distributions paid to noncontrolling interests	(893)														(893)
Change in cumulative foreign currency translation adjustment	(3,943)			(3,943)									(3,943)
Change in fair value cash flow hedge, net of taxes	0
Change in fair value of cash flow hedge from prior periods reclassified to earnings	3,687			3,687									3,687
Net income (loss)	33,608			10,650										10,650	22,958
Issuance of stock for acquisitions (in shares)								2,465,294
Issuance of stock for acquisitions		$ 63,311			$ 63,311						$ 63,311
Forfeiture of restricted stock (in shares)							(26,710)
Forfeiture of restricted stock	(75)			(75)						(75)
Contribution from noncontrolling partner	19,139														19,139
Sale to noncontrolling interests, net of taxes	$ 6,623			6,623						6,623
Ending balance (in shares) at Dec. 31, 2022	53,548,227						57,723,125
Ending balance, value at Dec. 31, 2022	$ 491,452			$ 332,995			$ 6			$ 436,288			$ (20,677)	$ (82,622)	$ 158,457